Experimental estimate · v0.2

Peru dengue outbreak

Peru2024 · weeks 1–23
Estimated USU1.9 million

Acute dengue symptoms

Reported deaths207

Source discrepancy: summary says 203. Source context

Population modeled249,843

reported cases

Approximate, assumption-based USU for the included experience. Deaths are a separate measure.

What this estimate tells us

The model assigns about 7.6 USU to each reported case. Peru and Brazil use exactly the same dengue assumptions, so the difference between these two estimates comes entirely from their reported case counts.

The inputs behind the estimate

249,843 × 5 days × 24 hours × 3 ÷ 47.25
≈ 1.9 million USU

7.6 USU per modeled course, before multiplying by the reported count. The calculation uses unrounded values; only the headline is rounded.

Intensity is assigned on a 0–10 scale and averaged over the whole elapsed course, including relief and sleep. Why divide by 47.25?

Duration assumption

5 days

WHO describes acute symptoms lasting 2-7 days. Five days is a rounded representative choice inside that interval, not a measured mean for any listed outbreak. Later fatigue is excluded. [S2]

Intensity assumption

3 / 10

Fever, headache, body/joint aches and nausea support a meaningful acute symptom burden. Assigned intensity 3 is a working average across the whole day, including relief and sleep. It is lower than a severe-pain peak. WHO does not establish the value 3 or its ratio to the reference. [S2]

All dengue entries share this exact template. A revision applies to every linked entry. Case definitions and reporting coverage still differ across sources.

How much can the assumptions change the result?

At 3 days and intensity 2, the result is about 0.76 million USU. At 7 days and intensity 4, it is about 3.6 million USU.

These are alternative input scenarios, not confidence intervals or bounds on all uncertainty. Some cross-condition orderings change under these choices. The headline uses the single shared template above.

What goes into this number?

Included

A single acute symptom course for every reported case, combining fever, aches, headache and nausea.

Source population and period

PAHO/WHO, 18 June 2024, p. 4: 249,843 reported cases through EW 23. The Andean series is described as suspected cases. No correction for missed or misclassified cases is applied. [S1]

Outside this estimate

Later fatigue, prolonged recovery, separate severe-case templates, caregiver distress, unreported infections and post-death loss.

Omitted experiences are unestimated, not known to be zero. This is not a complete event total or a guaranteed lower bound.

Whole representative courses are assigned to the source-defined cases or cohort. Course time can extend beyond the reporting dates. Individual trajectories, fatal-case truncation and a causal baseline are not reconstructed; no suffering after death is assigned.

Mortality source context

207 fatal cases on p. 4, consistent with its reported case-fatality rate; the p. 1 summary instead says 203. This source inconsistency is retained here and does not enter USU. [S1]

The country detail on page 4 reports 207 deaths; the summary on page 1 says 203. This report uses the country detail and keeps the discrepancy visible. Neither figure enters the USU calculation.

USU estimates experienced suffering during lived time. The death count is shown alongside it and is not converted into USU.

Sources and calculation data

Related reading

Dengue in the Americas: understanding the reported measures